FindTrial
Sign In

ALX148

DRUG2 trials

Sponsors

Alexander B Olawaiye, MD, QuantumLeap Healthcare Collaborative

Conditions

ER Positive Breast CancerEstrogen Receptor Positive TumorHER-2 Protein OverexpressionHER2 Low Breast CancerHER2 Low Breast CarcinomaHER2 Mutation-Related TumorsHER2-negative Breast CancerHER2-positive Breast Cancer

Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program
RecruitingNCT05868226
QuantumLeap Healthcare CollaborativeER Positive Breast Cancer, Estrogen Receptor Positive Tumor, HER2 Low Breast Cancer +18
Start: 2023-02-15End: 2029-12-30Target: 124Updated: 2025-04-04

Phase 2

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Active, not recruitingNCT05467670
Alexander B Olawaiye, MDOvarian Cancer
Start: 2023-03-30End: 2031-01-22Updated: 2026-03-04

Related Papers

Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
Clinical Cancer Research2026-02-17
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).
Journal of Clinical Oncology2024-06-011 citations